Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement
    on the ADA Request for Independent Review of Incretin-Based Therapies

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 13, 2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 13, 2013 /PRNewswire/ --Boehringer
Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY)
support the American Diabetes Association (ADA) call for an independent review
of the safety data of incretin-based therapies. At BIPI and Lilly, patient
safety is our top priority, and we support ongoing efforts to further
understand whether diabetes or certain diabetes treatments may affect the risk
of pancreatitis and pancreatic cancer.

We welcome future discussion with the ADA to determine how best we can support
this initiative and to provide a valuable contribution.

BIPI and Lilly also welcome the discussions taking place this week at the
National Institute of Diabetes and Digestive and Kidney Diseases–National
Cancer Institute (NIDDK-NCI) Pancreatitis, Diabetes and Pancreatic Cancer
Workshop. The workshop was convened, in part, to examine the latest data on
whether there is a potential risk of pancreatitis and pancreatic cancer in
people with type 2 diabetes as well as those treated with drugs classified as
incretin-based therapies.

About Diabetes
Approximately 25.8 million Americans^1 and an estimated 371 million people
worldwide^2 have type 1 or type 2 diabetes. Type 2 diabetes is the most common
type, accounting for an estimated 90 to 95 percent of all diabetes cases.^1
Diabetes is a chronic condition that occurs when the body does not properly
either produce or use the hormone insulin.^3 Diabetes was estimated to cost
the U.S. $245 billion in 2012.^4

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an
alliance in the field of diabetes that centers on three compounds representing
several of the largest diabetes treatment classes. This alliance leverages the
companies' strengths as two of the world's leading pharmaceutical companies,
combining Boehringer Ingelheim's solid track record of research-driven
innovation and Lilly's innovative research, experience, and pioneering history
in diabetes. By joining forces, the companies demonstrate commitment in the
care of patients with diabetes and stand together to focus on patient needs.
Find out more about the alliance at or

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the
largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT)
and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 140
affiliates and more than 46,000 employees. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel medications of high therapeutic value for
human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture.
Involvement in social projects, caring for employees and their families, and
providing equal opportunities for all employees form the foundation of the
global operations. Mutual cooperation and respect, as well as environmental
protection and sustainability are intrinsic factors in all of Boehringer
Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7
billion euro). R&D expenditure in the business area Prescription Medicines
corresponds to 22.5% of its net sales.

For more information please visit

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, IN, Lilly provides answers –
through medicines and information – for some of the world's most urgent
medical needs. Additional information about Lilly is available at

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world's first commercial insulin. Today we work to meet the diverse needs
of people with diabetes through research and collaboration, a broad and
growing product portfolio and a continued commitment to providing real
solutions – from medicines to support programs and more – to make lives

For more information, visit



Catherine London
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Phone: (317) 651-9116


1.Centers for Disease Control and Prevention. National diabetes fact sheet:
    national estimates and general information on diabetes and pre-diabetes in
    the United States, 2011. Atlanta, GA: U.S. Department of Health and Human
    Services, Center for Disease Control and Prevention, 2011.
2.International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact
    Sheet. 2012.
3.International Diabetes Federation. IDF Diabetes Atlas, 5th Edition: What
    is Diabetes?
    Accessed on: July 27, 2012.
4.American Diabetes Association. Diabetes Care. 2013; 36(4):1033-1046.


SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.